Key Plasma Fractionation Market Players:
- CSL Behring (Australia)
- Takeda Pharmaceutical Company (Japan)
- Grifols (Spain)
- Octapharma (Switzerland)
- Kedrion Biopharma (Italy)
- Biotest (Germany)
- ADMA Biologics (U.S.)
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- CSL Behring is a leading manufacturer of plasma-derived therapies that uses plasma fractionation as a core technology. The company’s integrated operations are structured around plasma collection, fractionation, purification, and finished-product manufacturing.
- Grifols is a central player in this sector and is a major plasma-derived medicines manufacturer with extensive fractionation and purification capabilities. Its portfolio includes immunoglobulins, albumin, and coagulation therapies.
- Octapharma manufactures plasma-derived and recombinant therapeutic proteins, with key products being immunoglobulins, albumin, and coagulation therapies. The firm’s integrated production process covers plasma fractionation, purification, virus safety, filling, and quality control.
- Takeda Pharmaceutical Company is yet another major manufacturer of plasma-derived therapies, which consists of an integrated business spanning plasma collection, fractionation, purification, and finished-product manufacturing.
- Kedrion Biopharma specializes in terms of plasma-derived therapeutic products, i.e., immunoglobulins, albumin, and coagulation factors. In addition, the company’s integrated manufacturing network and research into underutilized plasma fractions support its strong position in the global market.
Here is a list of key players operating in the global market:
The global plasma fractionation market is relatively consolidated, and it hosts a small group of large manufacturers holding broad geographic coverage and extensive portfolios, i.e., immunoglobulins, albumin, coagulation factors, and other plasma-derived therapies. CSL Behring, Takeda, Grifols, and Octapharma are among the leading global participants, which are effectively supported by integrated plasma collection, fractionation, purification, and finished-product manufacturing capabilities. Competition in this sector is structured around plasma availability, manufacturing capacity, and product innovation. In this context, Takeda in June 2024 announced an investment of USD 230 million to expand plasma fractionation capacity at its Los Angeles manufacturing site, thereby adding up to 2 million liters of annual capacity.
Corporate Landscape of the Market: